Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 24, 2011, Pages 7483-7488

  Miles, Timothy J ^a   Barfoot, Christopher ^b   Brooks, Gerald ^b   Brown, Pamela ^b   Chen, Dongzhao ^c   Dabbs, Steven ^b   Davies, David T ^b   Downie, David L ^b   Eyrisch, Susanne ^b   Giordano, Ilaria ^a   Gwynn, Michael N ^c   Hennessy, Alan ^b   Hoover, Jennifer ^c   Huang, Jianzhong ^c   Jones, Graham ^b   Markwell, Roger ^b   Rittenhouse, Stephen ^c   Xiang, Hong ^c   Pearson, Neil ^c  

^a GLAXOSMITHKLINE   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Antibacterials; Bacterial type IIA topoisomerase; Cyclohexyl amides; In vivo efficacy; Pharmacokinetic

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BACTERIAL TYPE IIA TOPOISOMERASE; CIPROFLOXACIN; CYCLOHEXYL AMIDE DERIVATIVE; DNA TOPOISOMERASE; NOVOBIOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RAT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

AMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BINDING SITES; COMPUTER SIMULATION; DNA TOPOISOMERASES, TYPE II; DOGS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HAPLORHINI; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN STRUCTURE, TERTIARY; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 81255157631     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.09.114     Document Type: Article

References (26)

1. D.J. Payne, M.N. Gwynn, D.J. Holmes, and D.L. Pompliano Nat. Rev. Drug Disc. 6 2007 29
2. C. Nathan Nature 431 2004 899
3. Y. Fukuda Drugs Future 34 2009 127
4. L.A. Mitscher Chem. Rev. 105 2005 559
5. A.J. Mehlholm, and D.A. Brown Ann. Pharmacother. 41 2007 1859
6. L.B. Rice Curr. Opin. Microbiol. 12 2009 476
7. M.T. Black, T. Stachyra, D. Platel, A.M. Girard, M. Claudon, J.M. Bruneau, and C. Miossec Antimicrob. Agents Chemother. 52 2008 3339
8. B.D. Bax, P.F. Chan, D.S. Eggleston, A. Fosberry, D.R. Gentry, F. Gorrec, I. Giordano, M.M. Hann, A. Hennessy, M. Hibbs, J. Huang, E. Jones, J. Jones, K.K. Brown, C.J. Lewis, E.W. May, M.R. Saunders, O. Singh, C.E. Spitzfaden, C. Shen, A. Shillings, A.J. Theobald, A. Wohlkonig, N.D. Pearson, and M.D. Gwynn Nature 466 2010 935
9. L. Gomez, M.D. Hack, J. Wu, J.J.M. Wiener, H. Venkatesan, A. Santillan, D.J. Pippel, N. Mani, B.J. Morrow, S.T. Motley, K.J. Shaw, R. Wolin, C.A. Grice, and T.K. Jones Bioorg. Med. Chem. Lett. 17 2007 2723
10. J.J.M. Wiener, L. Gomez, H. Venkatesan, A. Santillan, B.D. Allison, K.L. Schwarz, S. Shinde, L. Tang, M.D. Hack, B.J. Morrow, S.T. Motley, R.M. Goldschmidt, K.J. Shaw, T.K. Jones, and C.A. Grice Bioorg. Med. Chem. Lett. 17 2007 2718
11. B. Geng, J. Comita-Prevoir, C.J. Eyermann, F. Reck, and S. Fisher Bioorg. Med. Chem. Lett. 21 2011 5432
12. For the syntheses of these compounds and experimental details for the reactions in this paper see Brooks, G.; Davies, D. T.; Jones, G. E.; Markwell, R. E.; Pearson, N. D. WO2003087098; Chem. Abstr. 2003, 139, 337959.
13. Axten, J. M.; Daines, R. A.; Davies, D. T.; Gallagher, T. F.; Jones, G. E.; Miller, W. H.; Pearson, N. D.; Pendrak, I. WO2004002992; Chem. Abstr. 2004, 140, 94053.
14. Davies, D. T.; Elder, J. S.; Forrest, A. K.; Jarvest, R. L.; Pearson, N. D.; Sheppard, R. J. WO2004014361; Chem. Abstr. 2004, 140, 199210.
15. C. Barfoot, G. Brooks, P. Brown, S. Dabbs, D.T. Davies, I. Giordano, A. Hennessy, G. Jones, R. Markwell, T. Miles, N. Pearson, and C.A. Smethurst Tetrahedron Lett. 51 2010 2685 2689
16. C.W. Barfoot, P. Brown, S. Dabbs, D.T. Davies, A.J. Hennessy, T.J. Miles, and N.D. Pearson Tetrahedron Lett. 51 2010 5038 5040
17. C. Barfoot, G. Brooks, D.T. Davies, J. Elder, I. Giordano, A. Hennessy, G. Jones, R. Markwell, M. McGuire, T. Miles, N. Pearson, G. Spoors, R. Sudini, H. Wei, and J. Wood Tetrahedron Lett. 51 2010 2846 2848
18. H.M. Schwartz, W. Wu, P.W. Marr, and J.B. Jones J. Am. Chem. Soc. 100 1978 5199
19. R.E. Moses, and C.C. Richardson Proc. Natl. Acad. Sci. U.S.A. 67 1970 674
20. S. Winston, and T. Masushita J. Bacteriol. 123 1975 921
21. N. Bosworth, and P. Towers Nature 341 1989 167
22. J.C. Hancox, M.J. McPate, A. El Harchi, and Y.H. Zhang Pharmacol. Ther. 119 2008 118
23. M. Recanatini, A. Cavalli, and M. Masetti ChemMedChem 3 2008 523
24. Z. Zhou, Q. Gong, B. Ye, Z. Fan, J.C. Makielski, G.A. Robertson, and C.T. January Biophys. J. 74 1998 230
25. For hERG inhibition reviews: C. Jamieson, E.M. Moir, Z. Rankovic, and G. Wishert J. Med. Chem. 49 2006 4029
26. All animal experiment protocols were approved by the Animal Care and Use Committee at GlaxoSmithKline Pharmaceuticals (PA, USA). The pharmacokinetics of compound 7 were studied in male Sprague-Dawley rats, male Beagle dogs and male cynomolgus monkeys following single intravenous and oral administration. Absolute oral bioavailability was estimated using a cross-over study design (n = 3). Blood samples were assayed using protein precipitation followed by LCMS/MS analysis and the concentration-time data were analyzed by non-compartmental methods (WinNonlin, v3.2). The in vitro plasma protein binding and microsomal intrinsic clearance were determined as described in H. Xiang, J. McSurdy-Freed, G.S. Moorthy, E. Hugger, R. Bambal, C. Han, S. Ferrer, D. Gargallo, and C.B. Davis J. Pharm. Sci. 95 2006 2657